Phase I dose-escalation study of buparlisib (BKM120), an oral pan-class I PI3K inhibitor, in Japanese patients with advanced solid tumors.
Bottom Line: Secondary objectives included safety and tolerability, pharmacokinetics, antitumor activity and pharmacodynamic marker changes.Pharmacokinetic results showed that buparlisib was rapidly absorbed in a dose-proportional manner.Best overall response was stable disease for six patients, including one unconfirmed partial response.
Affiliation: Nagoya University Hospital, Nagoya, Japan.Show MeSH
Related in: MedlinePlus
Mentions: The best overall response was stable disease for six patients and progressive disease for seven patients (Table3; Fig.2). The best percentage change from baseline in target lesions for all patients is also shown in Fig. S1. The duration of stable disease ranged from 55 to 116 days. The disease control rate, defined as rates of complete response plus partial response plus stable disease, was 40%.